Science is advancing faster than ever. For the first time, ending malaria in our lifetime is a real possibility. New vaccines, treatments, malaria control tools and pioneering technologies - including genetic modification of mosquitos and long-acting injectables - are in development. Already, 25 countries are rolling out malaria vaccines to protect 10 million children a year. Next-generation mosquito nets now make up 84% of all new nets distributed. Nationally-led programmes are driving change. The possibility has never been greater.
On World Malaria Day 2026, the World Health Organization joins partners to launch the campaign: "Driven to End Malaria: Now We Can. Now We Must." This is a rallying cry to grasp the moment—to protect lives now and fund a malaria-free future.
Source: https://chrysalishigh.com/blog/health-nutrition/world-malaria-day/
The state of the fight
Progress is real and measurable
Since 2000, 2.3 billion cases and 14 million deaths have been averted. To date, 47 countries have been certified malaria-free (of which two in 2024 and three in 2025), while 37 countries reported fewer than 1000 cases in 2024. Success is possible, even in tough areas: The Greater Mekong Subregion proves elimination is achievable, with cases falling by nearly 90% despite long-standing drug resistance.
Between 2000 and 2024, the number of malaria-endemic countries fell sharply, dropping from 108 to 80. Over the same period:
- Countries with fewer than 10 000 cases rose from 27 in 2000 to 46 in 2024.
- Countries with fewer than 100 indigenous cases increased from 6 to 26.
- Countries with fewer than 10 indigenous cases increased from 4 to 24.
But the global situation is stalling: In 2024, there were an estimated 282 million cases and 610,000 deaths—a slight increase from 2023.
According to the World Malaria Report 2025, progress is at risk:
- Drug resistance: Artemisinin partial resistance is confirmed in four African countries (Eritrea, Rwanda, Uganda, United Republic of Tanzania,) and spreading. This is a critical danger to the main treatments for malaria.
- Insecticide resistance: Resistance to pyrethroids (the main chemical on bed nets) is widespread, confirmed in 48 out of 53 reporting countries.
- Diagnostic failure: pfhrp2 gene deletions, which can make rapid diagnostic tests fail, are spreading and now reported in 46 endemic countries.
- Invasive mosquitoes: Anopheles stephensi, an urban-dwelling, insecticide-resistant mosquito, is expanding its range in Africa, posing a new threat to cities.
- A massive funding gap: 2024 funding (US$ 3.9 billion) was less than half of the US$ 9.3 billion 2025 target. A projected shortfall of US$ 5.4 billion leaves the response dangerously under-resourced.
- Fragility of aid: Recent cuts in global health aid have disrupted health systems, surveillance, and campaigns, demonstrating how quickly progress can be undone.
- Humanitarian & environmental challenges: Climate change, conflict, and humanitarian crises continue to drive malaria resurgence and disrupt essential services.
Bright Spots
Despite the challenges, several interventions are being successfully scaled up and showing impact:
- New-Generation nets: In 2024, 84% of nets shipped to Africa were the more effective PBO or dual active ingredient nets, up from just 10% in 2019.
- Vaccines: A major breakthrough. To date, vaccines are rolling out in 25 countries, protecting millions of children.
- Chemoprevention: Seasonal malaria chemoprevention (SMC) now reaches 54 million children. Perennial malaria chemoprevention (PMC) is also expanding.
- Improved treatment of children: More febrile children are being diagnosed and treated with effective medicines (ACTs) than in the past.
To make a malaria-free future a reality, we must:
- Sustain & scale funding, with efficiency: Commit to sustained, diversified financing—both international and domestic. In an era of real financial constraints, every dollar must work harder. We must prioritize high-impact, data-driven interventions and deliver optimized responses that maximize value and minimize waste. Funding is what gets new vaccines, treatments, and tools out of labs and into the communities that need them most.
- Champion country leadership: Support nationally-led programmes that are driving change and tailor interventions to local needs for maximum impact. Strong national ownership is the foundation of an efficient and sustainable response.
- Ensure consistent partner support: Progress depends on predictable, aligned, and consistent support from all partners. Sustainable gains are built not on sporadic commitments, but on reliable collaboration that allows countries to plan and implement for the long term.
- Accelerate innovation: Continue to invest in research and development for new generations of tools, including those to beat insecticide, diagnostic and drug resistance.
- Empower communities: Engage and resource communities as protagonists in their own health, everyone has a role to play.
* With the tools and resources available today, no one should die from malaria.
A Disease That Should Not Still Be Killing People, Yet Here We Are
Every year on 25 April, the world marks World Malaria Day, not as a celebration, but as a reckoning. A moment to measure the distance between where we are and where we need to be in the fight against one of humanity’s oldest, most persistent killers.
The distance, in 2026, is both narrower and wider than it looks. Narrower, because the progress over the past two decades is genuinely extraordinary: 2.3 billion cases averted, 14 million deaths prevented, and 47 countries now certified malaria-free since 2000. Wider, because the WHO World Malaria Report 2025 tells us that an estimated 282 million people still contracted malaria in 2024, and 610,000 of them died – the vast majority being children under five in sub-Saharan Africa, in a disease that is fully preventable and fully treatable.
That tension, extraordinary progress sitting alongside extraordinary failure, is precisely what the 2026 theme captures. “Driven to End Malaria: Now We Can. Now We Must.” is not a tagline. It is an argument. The tools exist. The science is there. The blueprint is written. What remains is the will, the funding, and the follow-through.
India’s story within this global narrative deserves attention, because it shows what political commitment, community reach, and sustained investment achieve when they work in tandem. It is also a story that is far from over.
(Source: https://geimshospital.com/blog/world-malaria-day/)
World Malaria Day 2026: The Day, the Theme, and Why it Hits Different This Year
World Malaria Day was established by WHO Member States at the 60th World Health Assembly in May 2007 and first observed on 25 April 2008. It grew out of Africa Malaria Day, a regional observance held since 2001, and was elevated to a global platform to reflect the true scale of the challenge. The mandate was clear: provide education, build awareness, and sustain political and financial commitment for malaria prevention, control, and elimination worldwide.
Each year, the day anchors itself to a theme that reflects the most pressing priority of that moment. Looking at the arc of themes tells you everything about how the fight has evolved:
| Year | Theme |
| 2022 | Harness Innovation to Reduce the Malaria Disease Burden |
| 2023 | Time to Deliver Zero Malaria: Invest, Innovate, Implement |
| 2024 | Accelerating the Fight Against Malaria for a More Equitable World |
| 2025 | Malaria Ends with Us: Reinvest, Reimagine, Reignite |
| 2026 | Driven to End Malaria: Now We Can. Now We Must. |
* What the 2026 Theme is Really Saying
“Now We Can” refers to a specific set of breakthroughs that have fundamentally changed what is possible in malaria control:
- Two malaria vaccines – RTS,S/AS01 and R21/Matrix-M – now roll out across 25 countries, protecting millions of children for the first time in history.
- Next-generation insecticide-treated bed nets combining dual active ingredients (PBO and pyrethroids) work against mosquitoes that have developed resistance to standard nets. In 2024, 84% of nets shipped to Africa were these advanced nets – up from just 10% in 2019.
- Seasonal Malaria Chemoprevention now reaches 54 million children across 19 countries.
- Phase 3 results for ganaplacide-lumefantrine signal that the next generation of therapeutics is arriving. It is the first novel-acting treatment innovation in acute malaria since 1999.
“Now We Must” is where honesty comes in. Having the tools is not the same as using them. In 2024, global malaria funding reached $3.9 billion, less than half of the $9.3 billion needed to keep the response on track. That gap does not stay on a spreadsheet. It shows up as bed nets not delivered, tests not conducted, and treatments not reaching the people who need them most.
The 2026 theme, read together, is a call to match science with the will. We are closer to ending malaria than at any point in history. The question this World Malaria Day asks is whether that is close enough to act on.